Parkinson's
Vision – Vision – Improve the health and lives of people with Parkinson's disease through innovative,
Mission – To support high impact Parkinson's research that alters disease progression, improves disease symptoms, and develops treatments that benefit Service members and their families, Veterans, and the general public.
Parkinson's disease (PD) is a degenerative movement disorder of the central nervous system resulting from a loss of neurons in a region of the brain called the substantia nigra. These neurons produce dopamine, a neurotransmitter important for motor control; however, as PD progresses, the death of dopaminergic neurons results in reduced dopamine levels and impairment of motor control.
For FY22, Congress transitioned the Neurotoxin Exposure Treatment Parkinson's (NETP) program to the Parkinson's Research Program (PRP) and broadened the research from neurotoxin exposure treatment PD research to all types of PD research. The PRP challenges the scientific community to develop the most impactful research that will advance the understanding of the disease, with the ultimate goal of ending PD.
For information on toxic exposure research, please go to the Toxic Exposures Research Program at CDMRP.
Congressional Appropriations
- $48 million
FY22-24
Funding
Summary
- 32 Awards in FY22-23
- Recent Applications Recommended for Funding
Programmatic
Panels
Peer Review Participants
Last updated Friday, October 24, 2025

